Riggioni, CarmenComberiati, PasqualeGiovannini, MattiaAgache, IoanaAkdis, MübeccelAlves-Correia, MagnaAnto, Josep MArcolaci, AlessandraAzkur, Ahmet KursatAzkur, DilekBeken, BurcinBoccabella, CristinaBousquet, JeanBreiteneder, HeimoCarvalho, DanielaDe-Las-Vecillas, LeticiaDiamant, ZuzanaEguiluz-Gracia, IbonEiwegger, ThomasEyerich, StefanieFokkens, WytskeGao, Ya-DongHannachi, FarahJohnston, Sebastian LJutel, MarekKaravelia, AspasiaKlimek, LudgerMoya, BeatrizNadeau, Kari CO'Hehir, RobynO'Mahony, LiamPfaar, OliverSanak, MarekSchwarze, JürgenSokolowska, MilenaTorres, María Jvan-de-Veen, Willemvan-Zelm, Menno CWang, De YunZhang, LuoJimenez-Saiz, RodrigoAkdis, Cezmi A2023-02-092023-02-092020-06-20Riggioni C, Comberiati P, Giovannini M, Agache I, Akdis M, Alves-Correia M, et al. A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Allergy. 2020 Oct;75(10):2503-2541http://hdl.handle.net/10668/15736In December 2019, China reported the first cases of the coronavirus disease 2019 (COVID-19). This disease, caused by the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), has developed into a pandemic. To date, it has resulted in ~9 million confirmed cases and caused almost 500 000 related deaths worldwide. Unequivocally, the COVID-19 pandemic is the gravest health and socioeconomic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence-based medical advice on SARS-CoV-2 and COVID-19. Although the majority of the patients show a very mild, self-limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID-19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a "cytokine storm" leading to acute respiratory distress syndrome, endothelitis, thromboembolic complications, and multiorgan failure. The epidemiologic features of COVID-19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID-19-related topics should be based on more coordinated high-quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS-CoV-2, COVID-19, and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development, and epidemiology. A total of 150 questions were answered by experts in the field providing a comprehensive and practical overview of COVID-19 and allergic disease.enCOVID-19SARS-CoV-2AllergyCoronavirus disease 2019Severe acute respiratory syndrome-related coronavirus 2BetacoronavirusCOVID-19Coronavirus InfectionsHumansHypersensitivityPandemicsPneumonia, ViralSARS-CoV-2research article32535955Restricted AccessSARS-CoV-2PandemiasEpidemiologíaAsmaAlergia e inmunologíaHipersensibilidad10.1111/all.144491398-9995PMC7323196https://europepmc.org/articles/pmc7323196?pdf=renderhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323196/pdf